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Purpose: This study explored opinions and attitudes of genetic counselors regarding 
three controversial applications of preimplantation genetic diagnosis (PGD): PGD for 
early-onset Alzheimer, use of embryos that are BRCA positive after PGD revealed no 
disease-free embryos to be available, and PGD to select against a variant of unknown 
significance (VUS) for Marfan syndrome.  Methods: Genetic counselors were contacted 
through the National Society of Genetic Counselors (NSGC) electronic mailing list.  
Inclusion criteria required that a participant was currently practicing as a genetic 
counselor, was a member of the NSGC, and has counseled patients about PGD.  Twenty-
nine participants volunteered to participate and 24 recorded interviews were transcribed 
for data analysis.  The survey consisted of 34 questions including demographic questions, 
qualitative questions about each of the three case scenarios, and general questions about 
PGD.  Qualitative analysis was performed using a conventional content analysis approach 
as described by Hsieh (2005).  Results: Themes common to all three scenarios included: 
necessity of appropriate/thorough counseling, the importance of the genetic indications, 
patient perceptions, and respect for patient autonomy in decision making.  Multiple 
themes were also described for each unique case scenario.  The majority (65%,15/23) of 
participants felt PGD for an adult-onset disorder was least controversial, and PGD for a 
VUS was most controversial.  Conclusion: Participants felt that PGD was appropriate for  
iv
life limiting conditions, cases where there was an established diagnosis with a known 
pathogenic mutation, and when symptom severity and disease burden were significant.  
Participants agreed that appropriate/thorough counseling was necessary, patient 
perceptions of ‘serious’ disease were critical, and patient autonomy were key factors 
when dealing with controversial applications of PGD.  Ultimately, genetic counseling is 
recommended and patients need to understand the benefits, disadvantages, and the 
potential outcomes of PGD in order to make the decision that is most appropriate for their 
families.  
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Chapter 1. Background  
First used in the 1990s to successfully prevent X-linked disease, preimplantation genetic 
diagnosis (PGD) is a technique designed to prevent genetic disorders from being 
inherited by future generations.  Individuals who carry a known genetic mutation or 
chromosome rearrangement can use PGD to identify embryos at risk of inheriting a 
genetic condition.  For couples at increased risk of having affected offspring, PGD is an 
alternative to prenatal diagnosis, via amniocentesis or chorionic villus sampling (CVS), 
in which selective termination is often used to avoid affected offspring (Chang et al., 
2011).   
 Since the 1990s, significant improvements have been made in the biopsy and 
molecular diagnosis techniques used for PGD, which have allowed for an increasing 
number of genetic disorders to be tested.  Indications for PGD include aneuploidy 
screening, structural chromosome rearrangements, hereditary diseases, human leukocyte 
antigen typing, and maternal-fetal blood incompatibility (Chang et al., 2011).  Disorders 
include, but are not limited to, Huntington's disease, Marfan syndrome, hereditary cancer 
syndromes, cystic fibrosis, and hundreds more (Brezina, Brezina, & Kearns, 2012).   
 For couples at risk for a genetic condition, there are several reproductive options.  
Couples could choose to remain child free or adopt in lieu of having a biological child.  
For those that decide to pursue a pregnancy, there are several options available to prevent 
the birth of an affected child.  One of these options is the use of donated gametes.  For  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example, intrauterine insemination or in vitro fertilization (IVF) using an unaffected 
sperm donor could be used in the case of X-linked or autosomal recessive conditions to 
greatly reduce the risk.  The use of donated oocytes from a healthy female can be used in 
conjunction with IVF to prevent autosomal recessive, X-linked, and mitochondrial 
conditions (Vergeer, Van Balen, & Ketting, 1998).  Other couples may choose to proceed 
with a natural pregnancy and may or may not use prenatal diagnosis by amniocentesis or 
CVS (Vergeer et al., 1998; Harper and Sengupta, 2012).   
 Amniocentesis is typically performed between 15 and 20 weeks gestation and 
results are received seven to 14 days later.  Since the timing of an amniocentesis only 
allows for second trimester termination, CVS is an alternative diagnostic procedure that 
can be done between approximately 10 and 12 weeks gestation and enables the option of 
first-trimester termination (Goldberg, Martin, Lebo, & Pedersen, 1993).   
 Preimplantation genetic diagnosis is a reproductive option that allows couples, in 
many cases, to avoid pregnancy termination.  Because the PGD technique requires a 
priori knowledge of the genetic condition, couples who choose PGD typically have had a 
previous diagnosis of a specific disorder, either in an affected child or in one of the 
members of the couple.  Alternatively, some couples may not have any history of a 
disorder but may be aware of a positive carrier status through routine genetic carrier 
screening.  However, PGD is not a simple process.  In addition to undergoing the physical 
and emotional challenges of IVF, couples often need to have unique, specific molecular 
tests designed and validated to carry-out the genetic testing (Coutelle et al., 1989).  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1.1 Preimplantation Genetic Diagnosis (PGD) and In Vitro Fertilization (IVF) 
 Preimplantation genetic diagnosis is performed in conjunction with IVF.  
Approximately four to six percent of IVF cycles in the United States utilize PGD and 
nearly 74% of fertility clinics offer PGD (Baruch, Kaufman, & Hudson, 2008).  For IVF, 
ovaries are stimulated using a combination of injectable hormones to produce a higher 
than usual number of mature follicles.  Under ultrasound guidance, oocytes are retrieved 
from the ovaries by follicular fluid aspiration and fertilized in the laboratory to create 
embryos (Coutelle et al., 1989).  The oocytes and embryos can be tested at various stages 
of development by biopsying cells through various micromanipulation procedures 
(Goldberg et al., 1993).   
 Preimplantation genetic diagnosis involves the biopsy of polar bodies, 
blastomeres, or trophectoderm from developing oocytes and embryos.  Polar body biopsy 
is useful for screening oocytes for maternal genetic abnormalities only, since no paternal 
genetic contribution is present.  In Germany and Italy, with strict regulations on embryo 
biopsy, polar body biopsy is preferred because it occurs before fertilization is complete 
(Brezina et al., 2012).  After fertilization, the resulting embryo goes through several 
stages of development.  Three days after the fertilization procedure, embryos reach the 
cleavage stage of development, and are approximately four to eight cells in size.  
Cleavage stage biopsy involves removing one or two cells called blastomeres, and was 
the most common biopsy method used in PGD for many years (Brezina et al., 2012).  
Five days after the fertilization procedure, the embryo has reached the blastocyst stage 
and is composed of two cell types: the inner cell mass and the trophectoderm.  The inner 
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cell mass is a collection of cells that eventually becomes the fetus.  Trophectoderm cells 
are fated to become the placenta.  Biopsy at the blastocyst stage consists of removing 
several trophectoderm cells.  Several studies suggest more accurate PGD results with this 
type of biopsy as opposed to cleavage stage biopsy (Brezina et al., 2012).  
 Genetic abnormalities are identified by a variety of methods such as: polymerase 
chain reaction (PCR), microarrays and fluorescence in situ hybridization (FISH) (Practice 
Committee of the American Society for Reproductive Medicine, 2004; Brezina et al., 
2012).  Embryos that are unaffected can then be transferred to the woman’s uterus five or 
six days after egg retrieval, or are cryopreserved for future use (Practice Committee of 
the American Society for Reproductive Medicine, 2004).  The goal of PGD is to only 
transfer embryos that are most likely to be unaffected by a genetic condition (Ehrich & 
Williams, 2010).   
 Although PGD reduces risk, it is not considered an alternative to prenatal genetic 
diagnosis.  Prenatal genetic diagnosis, through CVS or amniocentesis, is recommended to 
confirm the PGD results, given the limitations resulting from testing the minute amount 
of DNA from an embryonic cell (Practice Committee of the American Society for 
Reproductive Medicine, 2004).  However, PGD is an attractive means of excluding 
embryos with genetic abnormalities and its use is becoming increasingly common.   
1.2 Benefits and Limitations  
 The benefits of this technology include the avoidance of a genetic abnormality or 
inherited disease, as well as, the lessened chance of a couple being faced with the 
decision of pregnancy termination (Fragouli, 2007).  However, there are risks associated 
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with PGD.  Embryo biopsies may damage or destroy embryos, requiring that 
embryologists and laboratory technicians performing embryo biopsy are highly skilled 
(Baruch et al., 2008).  Removal of a cell from an embryo may also decrease implantation 
rates (Baruch et al., 2008).  According to Baruch, “in all cases of PGD, it is critical to 
know whether the positive effect of selecting “normal” embryos or those with the desired 
trait is worth the risks and potentially detrimental effect of removing a cell for 
analysis” (Baruch et al., 2009, p. 250).  
 With newer advancements in genetic diagnostic technology, the uses of PGD have 
expanded dramatically, and some of these newer uses are controversial.  Many 
individuals in the research, bioethics, and medical communities are concerned that non-
health-related traits or “positive traits” such as intelligence or athleticism could be 
selected for in the future.  Yet not all disease or non-health-related traits have an 
identified gene (Baruch et al., 2008).  Often, “positive traits” are associated with multiple 
genetic and environmental factors and cannot be identified through current genetic testing 
technologies.  Therefore, at the current time, parents are unable to select every 
characteristic or trait of their future child(ren).  Preimplantation genetic diagnosis is also 
unable to create new traits that do not otherwise exist in the parents.  PGD does not 
involve “genetic manipulation or “engineering” of the embryo itself” (Baruch et al., 
2009, p. 250).   
1.3 Current Applications of PGD  
 There are numerous reasons why couples may choose PGD testing.  These 
reasons include, but are not limited to: sex selection, a previously affected pregnancy/
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child, human leukocyte antigen (HLA) matching, one member of a couple is affected 
with a genetic condition or carries a balanced chromosomal rearrangement, advanced 
maternal age, and to increase the effectiveness of IVF by ruling out chromosomal causes 
of miscarriage and failed embryo implantation (Chang et al., 2011).  
 Initially, PGD was only used to identify embryos at risk for childhood-onset, 
single gene disorders.  Single gene disorders are caused by mutations in a specific gene; 
examples include cystic fibrosis, sickle cell disease, hemophilia and Marfan syndrome.  
In principle, PGD, is able to identify the same single gene disorders tested for by prenatal 
diagnosis (Chang et al., 2011).  In order for PGD to be performed for single gene 
disorders, a known disease-causing mutation must have been identified in the family 
(Handyside, Lesko, Tarin, Winston, & Hughes, 1992).   
 In the early 1990s, researchers attempted, for the first time, to identify embryos 
with cystic fibrosis using PGD (Handyside et at., 1992).  Cystic fibrosis is an autosomal 
recessive condition common in the Caucasian population, with an incidence of one in 
2500 live births and a carrier frequency of one in 25.  A mutation in the cystic fibrosis 
transmembrane regulator (CFTR) gene causes defective chloride ion transport, which 
leads to multiple medical complications affecting several organs including the lungs and 
pancreas (Cant, Pollock, & Ford, 2014).  In the study by Handyside et. al. (1992), three 
couples, all carrying the common delta F508 mutation in the CFTR gene, requested PGD 
to prevent the birth of children with cystic fibrosis.  Each couple had at least one 
previously affected child with cystic fibrosis and wished to avoid another affected child 
or pregnancy termination after prenatal diagnosis.  Couples were counseled about the 
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risks of the procedures and understood that, at the time, this was still an experimental 
treatment (Handyside et at., 1992).  Using polymerase chain reaction (PCR), researchers 
amplified the CFTR gene from single cells removed from the couples’ embryos and 
identified non-carrier, carrier, and affected embryos.  In one couple, a non-carrier embryo 
and a carrier embryo were both transferred on the same day of DNA analysis.  A 
pregnancy resulted and a female child was born, free of the parental mutations and 
therefore unaffected by cystic fibrosis.  Another couple also transferred both a carrier 
embryo and a non-carrier embryo; however, no pregnancy resulted.  A third couple did 
not undergo embryo transfer as none of their embryos were identified as free of the 
mutation (Handyside et at., 1992).  
 Some couples may choose to pursue PGD to select embryos that are a human 
leukocyte antigen (HLA) match for a sibling in need of a bone marrow transplant.  An 
HLA matched embryo allows for allogeneic haematopoietic stem cell (HSC) 
transplantation through cord blood or bone marrow donation from a healthy sibling to 
one who is ill (Pennings, Schots, & Liebaers, 2002).  In some conditions, a stem cell 
transplant from an HLA matched sibling is often the only cure (Pennings et al., 2002).   
 In 2001, the first case of PGD for an HLA matched sibling was successful for 
Fanconi anemia.  Fanconi anemia is an autosomal recessive condition that causes a 
multitude of congenital anomalies and developmental issues, and most affected 
individuals have a significantly shortened life span due to bone marrow failure and a 
significantly increased risk of developing leukemia (Kupfer, 2013).  Although many 
anomalies in Fanconi anemia may persist, the bone marrow failure and high risk for 
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leukemia may be successfully treated with a cord blood or bone marrow transplant.  The 
success rate of a bone marrow transplant to treat Fanconi anemia is significantly greater 
when the donor is an HLA matched sibling to the recipient.  When testing an embryo for 
HLA matching, testing for a single gene disorder can also be done at the same time to 
ensure that the embryo is also free of the genetic condition (Milachich et al., 2013).  In 
this first case, researchers were able to successfully identify and transfer embryos that 
were unaffected with Fanconi Anemia and were also an HLA match to the affected 
sibling (Verlinsky, Rechitsky, Schoolcraft, Strom, & Kuliev, 2001).  A healthy, HLA 
matched baby was born to this couple, and a successful bone marrow transplant was later 
performed on the affected child using umbilical cord blood collected from the newborn at 
the time of delivery.  Preimplantation genetic diagnosis has been used effectively for this 
purpose in similar situations, such as β-thalassemia, and severe combined 
immunodeficiency (SCID) (Milachich et al., 2013). 
 Another frequent indication for PGD is a balanced chromosomal rearrangement in 
one parent, such as an inversion or translocation (Alfarawati, Fragouli, Cools, & Wells, 
2011).  Balanced chromosomal rearrangements are the basis of recurrent miscarriages in 
five to 10 percent of couples (Vanneste et al., 2011).  Individuals who carry a balanced 
chromosome rearrangement are typically healthy but can produce unbalanced gametes.  
Embryos with unbalanced rearrangements often fail to implant or result in miscarriage, 
and therefore, couples in which one partner carries a balanced rearrangement are at 
increased risk for infertility and/or recurrent miscarriage.  If a live birth with an 
unbalanced rearrangement does occur, there are often birth defects, developmental 
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delays, and/or intellectual disabilities (Chang et al., 2011).  Alternatively, those who 
inherit balanced rearrangements from a parent, with no extra or missing genetic 
information, are not usually at increased risk for spontaneous abortion or developmental 
problems (Chang et al., 2011).  For carriers of balanced rearrangements, PGD to select 
against embryos carrying unbalanced chromosome rearrangements can reduce 
spontaneous abortion, minimize the risk of offspring inheriting a chromosome imbalance, 
and increase pregnancy rates (Vanneste et al., 2011).    
 Preimplantation genetic diagnosis can also be used to select against conditions 
that usually do not manifest until adulthood, such as Huntington’s disease or early-onset 
Alzheimer’s disease.  Huntington’s disease is an autosomal dominant neurodegenerative 
disorder affecting muscle control, cognitive functions, behavior and personality (Lee, 
Hwang, Hun, Kowall, & Ryu, 2013).  The majority of cases experience symptoms 
between the ages of 30 and 50 years old.  Alzheimer’s disease is another adult-onset, 
irreversible, progressive brain disease.  Most cases of Alzheimer’s disease occur after the 
age of 60, but there is also an early onset, monogenic form (Verlinsky et al., 2002).  
 The first use of PGD for early-onset Alzheimer’s disease occurred in the early 
2000s.  Three genes associated with this form of Alzheimer's disease are presenilin one 
(PSEN1), presenilin two (PSEN2), and amyloid precursor protein (APP) (Verlinsky et al., 
2002).  Mutations in these genes predispose a person to developing Alzheimer’s disease.  
Penetrance has not been established for all three genes, but mutations in the APP gene are 
known to be almost completely penetrant (Verlinsky et al., 2002).  In one case, a 30-year 
old female requested PGD because she carried a familial mutation in the APP gene.  
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Embryos without the familial mutation were identified and transferred.  A pregnancy was 
successfully established and verification of an unaffected fetus was obtained through 
CVS.  This case demonstrates the feasibility of using PGD for adult-onset predisposition 
genes, for conditions like Alzheimer’s disease (Verlinsky et al., 2002).  
1.4 Practice Guidelines in the Utilization of PGD 
 Preimplantation genetic diagnosis has several uses that push bioethical boundaries 
and thus are considered controversial.  For this reason, in many countries, there are 
professional organizations that provide guidance regarding the use of PGD.  These ethics 
committees include the Human Fertilization and Embryology Authority (HFEA) in the 
United Kingdom, and the American Society for Reproductive Medicine (ASRM) in the 
United States.  Both committees have published guidelines regarding use of PGD.  It is 
important to distinguish that the HFEA influences laws governing the use of PGD, versus 
ASRM which develops guidelines for healthcare providers.  There are no laws governing 
PGD in the United States, which is different from the United Kingdom.  American 
physicians can choose to implement or ignore guidelines, whereas British physicians are 
mandated by laws developed from HFEA regulations.  
 In the United Kingdom, the HFEA is the governing authority regarding the use of 
gametes and embryos in research and fertility treatment.  The HFEA determines the 
conditions for which PGD can be used and grants licenses for each condition 
(Ormondroyd et al., 2012).  According to the HFEA website, as of 2012, the HFEA 
allows for PGD to be performed for more than 350 genetic conditions.  Decisions 
regarding which conditions are allowed are guided by three ethical principles (Williams, 
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Ehrich, Farsides, & Scott, 2007).  First, the individual seeking PGD must feel that a 
condition is serious enough to cause them concern.  Second, there should be a significant 
risk that an embryo will have a serious genetic condition.  Third, indications for PGD 
should be similar to current practices in prenatal diagnosis (Williams et al., 2007).  When 
deciding which diseases can be tested by PGD, the HFEA also considers the suffering 
experienced by the affected individual and if there are effective treatments available.  In 
2006, HFEA supported “widening the scope for PGD to include susceptibility to late 
onset, lower penetrance conditions” (Williams et al., 2007, p. 1095).    
In the United States, the American Society of Reproductive Medicine (ASRM), 
has published several committee opinions regarding the use of PGD.  The ASRM 
recommends that couples considering PGD should receive genetic counseling.  Genetic 
counselors who handle PGD cases must relay to each couple information relating to risks 
associated with IVF, risks associated with biopsy and culture of embryos, inheritance, 
quality of life, possibility of misdiagnosis, prenatal diagnostic testing, the possibility that 
all embryos are affected, and alternative methods of avoiding disease (Practice 
Committee of the American Society for Reproductive Medicine, 2008).   
Regarding PGD for adult-onset conditions, ASRM concludes that PGD is 
ethically justified when a condition is serious and there are no safe and effective 
treatments available.  As a matter of reproductive liberty, ASRM also advocates for the 
ability to use PGD for less serious or lower penetrance conditions.  In the case of a single 
gene disorder, ASRM states that PGD is a significant advance over prenatal diagnosis and 
pregnancy termination (Ethics Committee of American Society for Reproductive 
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Medicine, 2013).  With regards to sex selection, ASRM concludes that PGD should only 
be allowed to prevent sex-linked genetic conditions from being transmitted and not as a 
means of family balancing (Ethics Committee of American Society for Reproductive 
Medicine, 2013).   
Although ASRM has published many committee opinions regarding the use of 
PGD, there are several recently evolved uses of PGD that have yet to be addressed with 
practice guidelines.  These include: PGD for a variant of unknown significance and use of 
embryos with genetic disease after PGD revealed no disease-free embryos to be 
available. 
1.5 Controversial Applications of PGD 
   1.5.1 Adult-onset Disorders.  PGD for couples whose offspring are at risk for adult-
onset conditions has raised concerns as these conditions do not occur until later in life.  
Approximately 28% of fertility clinics that responded to a 2005 survey reported that they 
have provided PGD to avoid serious adult-onset diseases (Baruch et al., 2008).  Many 
factors determine what conditions are “serious” including severity of symptoms, 
penetrance, potential for treatment, disease progression, heritability, and age of onset 
(Krahn, 2009).  
 The use of PGD to avoid offspring who have inherited mutations that predispose 
to diseases and are incompletely penetrant is also controversial.  For example, mutations 
in the BRCA1 and BRCA2 genes can confer predisposition to certain cancers but do not 
guarantee that cancer will occur (Ormondroyd et al., 2012).  In women, mutations in 
these genes confer a lifetime risk of up to 87% for developing breast cancer and up to a 
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44% lifetime risk of developing ovarian cancer.  Men who carry mutations in these genes 
have an increased risk of breast and prostate cancer.  Prior to 2006, HFEA only licensed 
conditions that had close to 100% penetrance, meaning individuals who had a mutation 
were nearly 100% likely to develop the disorder.  In 2006, the HFEA expanded its list of 
approved PGD uses to include cancer predisposition genes, including BRCA1 and BRCA2 
(Ormondroyd et al., 2012).  According to the HFEA, “in principle, it is appropriate that 
PGD be available for serious, lower penetrance, later-onset genetic conditions such as 
inherited breast, bowel, and ovarian cancer” (Krahn, 2009, p. 189).  Although some 
adult-onset conditions, such as breast cancer, can be successfully treated and are not 
necessarily fatal, the HFEA identifies them as “serious genetic conditions because they 
cause suffering and are life threatening,” and determines that “PGD should be available 
to test for these cancers” (Krahn, 2009, p. 189).  
   1.5.2 Variant of Unknown Significance.  A more recent development in the use of 
PGD comes from patient requests for selection against a genetic variant of unknown 
significance (VUS).  A VUS is a deletion, duplication, or nucleotide sequence change that 
has not been previously defined as deleterious and can be either inherited or de novo.  A 
genetic change categorized as a VUS has not been defined as clinically significant or 
predictive of an individual’s phenotype.  For individuals that have inherited a VUS, 
clinical significance and recurrence risk are often difficult to elucidate because of 
unknown factors such as variable expressivity and incomplete penetrance (Reiff et al., 
2012).   
!13
 This is another controversial issue faced by the PGD community, as it is not 
definitively known if a VUS is disease causing.  There is little published information 
about the experience of PGD laboratories in terms of testing for these variants.  However, 
according to a genetic counselor at Reproductive Genetics Institute (RGI) in Chicago, 
there are increasing requests for selection against a VUS in both situations where the 
VUS is believed (but not proven) to be disease causing, or where there is a significant 
degree of uncertainty surrounding a particular genetic disease (Besser, 2013).  One such 
disease is Marfan syndrome.  
 The first reported clinical use of PGD to avoid the inheritance of Marfan 
syndrome occurred in the mid 1990s (Harton et al., 1996).  Marfan syndrome is an 
autosomal dominant connective tissue disorder, which mainly affects the skeleton, eyes 
and cardiovascular system (Coron et al., 2012).  There is a wide range of phenotypic 
variability, and while some individuals have severe involvement of multiple organ 
systems, mildly affected individuals can remain undiagnosed for their entire lives without 
major health concerns (Harton et al., 1996).  Preimplantation genetic diagnosis is usually 
feasible if a known pathogenic mutation in the FBN1 gene is identified.  However, most 
mutations in the FBN1 gene are private, and therefore molecular sequencing of this gene 
often identifies a VUS.  Given the uncertainty surrounding a VUS and whether it is truly 
causing a patient’s clinical diagnosis of Marfan syndrome, it is often difficult to counsel 
patients about what this result can mean for future children.  Performing PGD for a VUS 
for Marfan syndrome does not guarantee that a child will not have Marfan syndrome, 
since it is possible that another pathogenic mutation exists but is unidentifiable with 
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current technologies.  Therefore, the appropriateness of PGD or prenatal diagnosis for a 
VUS is questionable, and with the increasing availability of multigene sequencing panels 
and whole exome/genome sequencing, is likely to become a frequent and significant 
issue in the field. 
   1.5.3 Use of embryos with genetic disease after PGD revealed no disease-free 
embryos to be available.  Another controversial use of PGD is use of embryos with 
genetic disease after PGD reveals no disease-free embryos.  Some couples deliberately 
select for a child with a genetic condition typically because at least one member of the 
couple has that disorder, like deafness or dwarfism (Baruch, 2009).  For example, a 
woman with achondroplasia may choose to implant embryos with the disorder because 
her small physical stature would affect her ability to carry an average size baby.  Several 
PGD laboratories have stated that individuals seeking to use PGD to intentionally select 
for diseases or disabilities would not be offered PGD (Baruch, 2009).  However, it is 
possible that during the PGD process, no healthy embryos are available for transfer.  In 
this situation, patients want a healthy child but do not have healthy embryos for transfer.  
Couples must then choose whether or not to start over or use one of the affected embryos.  
1.6 Ethical Considerations For The Use of PGD 
 Although a valuable and useful technique, PGD has ethical challenges associated 
with its uses.  Currently, there is much debate regarding the appropriate parameters for 
the use of PGD (David, Weitzman, Herve, & Fellous, 2012).  There is also discussion 
regarding whether PGD is “an obligation or good practice” (David et al., 2012, p. 625).   
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 Some argue that “it is time to recognize that impairments occur along a 
continuum” (Miller & Levine, 2013, p. 100).  On one end of this continuum there are 
conditions such as congenital deafness, which may not have a significant impact on 
health or life expectancy.  On the other end of the spectrum, conditions like Tay-Sachs 
disease cause significant suffering and a shortened lifespan.  It is argued that “value 
judgments regarding the quality of life of a person with a given disability must be made 
by the individual who lives with the disability, not by the researcher or clinician” (Miller 
& Levine, 2013, p100).  Many individuals with disabilities and/or genetic conditions 
have found their lives to be fulfilling and valuable.  The disability community has 
expressed concern about the intention and outcomes of genetic research; specifically, 
whether advances in genetic diagnostic technologies are intended to eliminate disability 
from the population.  Specifically, PGD is seen negatively by some members of the 
disability community, as its intention is to prevent the birth of individuals with disability 
(Miller & Levine, 2013).  Some equate this concern to the notion that there will be lower 
tolerance for individuals with disabilities, as well as increased injustice, stigmatization, 
and discrimination (Vergeer et al., 1998; Petersen, 2005).  For these reasons, some people 
in the disability community are wary of PGD and see it as a misuse of genetic 
technology.  
Others would argue that selection of embryos with a genetic condition is not 
the intended use of PGD, and that this technology is only intended to prevent the 
transmission of genetic diseases to future generations.  While PGD was not designed to 
select for children with diseases or disabilities, a survey performed in 2005 by Baruch et 
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al. found that three percent of fertility clinics reported having used PGD to select for a 
particular disease or disability.  In all cases, the conditions selected for were forms of 
deafness or dwarfism (Baruch et al., 2008).   
There are arguments that parents have the moral and ethical responsibility to 
select embryos that have the “best chance in life,” and therefore, embryos with a known 
genetic condition should not be selected for implantation.  Other factors to take into 
account when examining the ethics of reproductive decision-making include procreative 
autonomy and non-directive counseling (Savulescu, 2001).   
The basis of procreative autonomy is that couples are free to decide what kind 
of children to have, as well as when and how to have these children, even if that means 
they are selecting for a disability.  According to the principle of non-directive counseling, 
medical personnel should provide patients with information about risks and options to 
reduce these risks.  Specific advice or direction should not be given to patients.  This 
principle argues, for example, that if a couple knowingly chooses to transfer an embryo 
that is affected with a genetic disease, then the medical professional should not express 
agreement or disagreement about this decision (Savulescu, 2001).  
Some bioethicists argue that children have a right to an “open future” and if 
their parents choose to “unreasonably limit the life plans available to their child, the child 
suffers a moral harm” (Smolensky, 2008, p. 3).  However, what if prospective parents feel 
as though they have no other choice because all of their embryos are affected with a 
genetic condition?  According to some, there is a difference between choosing an embryo 
with a genetic predisposition when you have the option of another healthy embryo with 
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the “best” chance, and choosing an embryo with a genetic predisposition only because 
there are no “healthy” embryos.  The question becomes, should couples be able to use an 
affected embryo if no healthy ones are available?  
The goal of PGD is to produce healthy offspring by not implanting embryos 
that are affected with a known disease.  In the United States, the use of PGD is often 
determined by the IVF clinics and PGD laboratories.  Although there are professional 
guidelines to assist with decision-making, these guidelines do not address all possible 
scenarios that may arise.  As there are no regulations regarding the use of PGD, many 
genetic counselors and other IVF/PGD providers continue to face the ethical dilemmas 
described.  
1.7 Need for Current Study 
The purpose of this study is to explore the opinions and attitudes of genetic 
counselors who work with patients throughout the PGD process.  Another purpose is to 
determine common themes identified by genetic counselors regarding three controversial 
PGD case scenarios: PGD to select against an adult-onset condition, use of embryos with 
genetic disease after PGD revealed no disease-free embryos to be available, and PGD to 
select against a variant of unknown significance (VUS).  The information gained from 
this study will add perspectives from genetic counselors who work with PGD patients to 
the discussion concerning controversial applications of the technology.  Interviews will 
provide a more detailed description of ethical challenges experienced by genetic 





Chapter 2: Walking the Edge with Controversial Use of Preimplantation Genetic 
Diagnosis (PGD): Opinions and Attitudes of Genetic Counselors   1!
2.1 Abstract 
Purpose: This study explored opinions and attitudes of genetic counselors regarding 
three controversial applications of preimplantation genetic diagnosis (PGD): PGD for 
early-onset Alzheimer, use of embryos that are BRCA positive after PGD revealed no 
disease-free embryos to be available, and PGD to select against a variant of unknown 
significance (VUS) for Marfan syndrome.  Methods: Genetic counselors were contacted 
through the National Society of Genetic Counselors (NSGC) electronic mailing list.  
Inclusion criteria required that a participant was currently practicing as a genetic 
counselor, was a member of the NSGC, and has counseled patients about PGD.  Twenty-
nine participants volunteered to participate and 24 recorded interviews were transcribed 
for data analysis.  The survey consisted of 34 questions including demographic questions, 
qualitative questions about each of the three case scenarios, and general questions about 
PGD.  Qualitative analysis was performed using a conventional content analysis approach 
as described by Hsieh (2005).  Results: Themes common to all three scenarios included: 
necessity of appropriate/thorough counseling, the importance of the genetic indications, 
patient perceptions, and respect for patient autonomy in decision making.  Multiple 
themes were also described for each unique case scenario.  The majority (65%,15/23) of 
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participants felt PGD for an adult-onset disorder was least controversial, and PGD for a 
VUS was most controversial.  Conclusion: Participants felt that PGD was appropriate for 
life limiting conditions, cases where there was an established diagnosis with a known 
pathogenic mutation, and when symptom severity and disease burden were significant.  
Participants agreed that appropriate/thorough counseling was necessary, patient 
perceptions of ‘serious’ disease were critical, and patient autonomy were key factors 
when dealing with controversial applications of PGD.  Ultimately, genetic counseling is 
recommended and patients need to understand the benefits, disadvantages, and the 
potential outcomes of PGD in order to make the decision that is most appropriate for their 
families. 
Keywords: Preimplantation genetic diagnosis (PGD), controversial, genetic 
counselors’ opinions. 
2.2 Introduction  
 Since the 1990s, preimplantation genetic diagnosis (PGD) has been used to 
prevent genetic disorders from being inherited by future generations.  Individuals who 
carry a known genetic mutation or chromosome rearrangement can use PGD to identify 
embryos at risk of inheriting a genetic condition.  Indications for PGD include, but are 
not limited to: sex selection, a previously affected pregnancy/child, one member of a 
couple is affected with a genetic condition or both carry an autosomal recessive mutation, 
and to increase the effectiveness of IVF by ruling out aneuploidy, chromosomal causes of 
miscarriage and failed embryo implantation (Hershberger & Pierce, 2010; Chang et al., 
2011).  However, given the advancements in genetic testing and expansion of knowledge 
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in the field of genetics, PGD has been used for other indications, some of which are 
controversial.   
 Professional guidelines from the American Society of Reproductive Medicine 
(ASRM) and the Human Fertilization and Embryology Authority (HFEA) explicate 
appropriate utilization, yet these guidelines do not address all possible scenarios that may 
arise.  Therefore, many genetic counselors and other IVF/PGD providers continue to face 
ethical dilemmas.   
 Here we discuss the opinions of genetic counselors regarding three controversial 
uses of PGD: (1) PGD for early-onset Alzheimer, (2) transferring male embryos which 
carry a BRCA1 mutation when no unaffected embryos are produced, and (3) PGD for a 
variant of uncertain significance (VUS) for Marfan syndrome.   
2.3 Materials and Methods  
   2.3.1 Participants.  After receiving Institutional Review Board approval from the 
Office of Research Compliance, University of South Carolina, Columbia, SC, an 
invitational letter (Appendix A) was sent through the National Society of Genetic 
Counselors (NSGC) electronic mailing list to genetic counselors, inviting their 
participation in our study.  The inclusion criteria required that a participant was currently 
practicing as a genetic counselor, had counseled patients regarding the use of PGD, and 
was a member of the NSGC.  The Assisted Reproductive Technologies and Infertility 
Special Interest Group (ART/Infertility SIG) of the NSGC also forwarded an invitational 
letter to its members.  
!
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   2.3.2 Research Methods.  Individuals who responded to the invitational letter were 
asked for their verbal consent (Appendix B) before accruing into the study and 
proceeding with the survey (Appendix C).  Consenting participants were interviewed by 
telephone and all interviews were recorded to maintain the veracity of the data.  The 
survey consisted of 34 questions and required 25 to 45 minutes to complete (see 
Appendix C).  Six demographic questions were followed by qualitative, semi-structured, 
open ended questions about each of the three case scenarios (21 questions), and general 
questions about the use of PGD (7 questions).  No identifying information was collected.  
The survey questions were used to assess participants’ opinions and attitudes about each 
case scenario and their opinions on controversial uses of PGD technology.    
   2.3.3 Statistical Analysis.  The audio recorded interviews were transcribed and verified 
for accuracy by the principal investigator (first author).  Qualitative analysis was 
performed using a conventional content analysis approach as described by Hsieh & 
Shannon (2005).  This approach allows for the identification and coding of data that 
reflects the participants’ views and opinions of the scenarios presented.  During the 
analytic process, patterns emerged from the codes and were classified into categories.  
The categories formed the basis for emergent themes and sub-themes.  An advantage of 
conventional content analysis is that it gains “direct information from study participants 
without imposing preconceived categories or theoretical perspectives” (Hsieh & 
Shannon, 2005, p. 1279-1280).  Thus, this analytic method was selected for our study 
because it identifies themes that are intended to help understand participants’ unique 
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perspectives.  Consistent with content analysis, frequency counts were performed, when 
appropriate, during data analysis.  
2.4 Results 
 Twenty-nine participants volunteered for the study; two participants were 
excluded as they did not meet inclusion criteria.  Three audio recordings were unusable; 
therefore, a total of 24 recorded interviews were transcribed and used for data analysis.   
   2.4.1 Demographic Data.  Table 2.1 shows the distribution of participants’ gender, age, 
years of practice as a genetic counselor, number of years they have counseled for PGD, 
number of PGD cases seen per month, setting of practice, and region of practice.  The 
large majority of participants were women, 96% (23/24).  Most participants were 
between the ages of 25 and 30 years of age, 42% (10/24), and had less than one year to 
five years of experience practicing as a genetic counselor (54%, 13/24).  Fifty-four 
percent (13/24) had been counseling for PGD for zero to five years and 42% (10/24) 
typically counsel for PGD one to five times a month.  Six of the 24 participants counsel 
greater than 20 PGD cases a month.  The largest group of participants indicated that they 
were working in settings other than reproductive endocrinology clinics or PGD 
laboratories, 54% (13/24).  These settings included maternal fetal medicine clinics, 
pediatric clinics, and adult clinics.  Twenty-five percent (6/24) indicated they worked in a 
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   2.4.2 Conventional content analysis.  Conventional content analysis was used to 
analyze data obtained from recorded interviews. Themes and key words were identified 
from answers given by each of the 24 participants and quotes were used to illustrate and 
support the identified themes.  Frequency counts were also used for certain questions. 
   2.4.3 PGD for an adult-onset condition.  For PGD for early-onset Alzheimer’s 
disease, participants were first asked if this scenario raised any concerns for them, and if 
so, what concerns were raised.  Of the 24 participants, 58% (14/24) stated that PGD for 
this reason raised no concerns and 43% (6/14) of those participants were not concerned 
because of patient autonomy.  From those 14 participants, 21% (3/14) stated they were 
comfortable offering PGD for any adult-onset condition including early-onset Alzheimer.  
Forty-six percent (11/24) of participants raised several concerns.  Several themes 
emerged, including: effects on counselors’ comfort, psychosocial topics, and autonomy of 
the child and spouse.  
   2.4.3.1 Effects on counselors’ comfort levels. 
Necessity of appropriate/thorough counseling  
 Several commonly shared concerns regarding PGD for adult-onset conditions 
were noted.  For 17% (4/24) of the counselors interviewed, the specific mutation in the 
discussed scenario predisposed, but did not guarantee, a person to have early onset 
disease.  Therefore, penetrance of the condition affected counselors’ comfort levels of 
using PGD:  
!
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“I think one of my main concerns is whether it is one of those conditions for 
which having the mutation is a given to getting the diagnosis or it is a pre-
disposing factor so those conditions that PGD would be used to detect 
predisposition I think are a little harder to swallow ethically than those which the 
mutations kind of equals the disease state at some point” (S) 
“I think that if it were a highly penetrant mutation, my concerns would be 
lessened…” (B).   
Having a known mutation influenced 13% (3/24) of participants’ comfort level for 
offering PGD: 
“It doesn’t raise any significant concerns for when there is a clear genetic cause 
that leads to an increased risk for an adult-onset condition such as early onset 
Alzheimer…” (K) 
“I think people should be able to do this for any reason that they choose as long 
as there is evidence to support that it should be done…” (F). 
 If patients choose to pursue PGD for an adult-onset condition, 29% (7/24) of 
participants agreed that it is the patient’s right: 
“I don’t feel that it is my place as a counselor to tell that couple that they 
couldn’t use it…” (W) 
“I just try and let my patients make the choice that’s right for them” (C). 
Three participants (13%, 3/24) wanted patients to understand that otherwise healthy 
embryos could be discarded and potentially their could be future treatments: 
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“Part of the genetic counseling for PGD is making sure that the couple is aware 
of the implications of discarding otherwise healthy embryos” (N)  
“A potential concern would be the possibility of anything adult-onset, is will 
treatment become available by the time a potentially affected child would be born 
and have and be at risk for this” (Q).  
   2.4.3.2 Psychosocial Topics.  Twenty-one percent (5/24) of participants considered the 
patient’s perception of which conditions were “serious enough,” concerning, or 
burdensome as important and 20% (1/5) of these participants considered PGD an 
opportunity to spare the child: 
“Ultimately is that something that the patient wanted to do and felt that it was 
important enough…I would continue to counsel them appropriately” (B) 
“What I always try to tell my patients to think about is how burdensome has this 
disease been in your own life…for some patients it feels like a huge huge burden 
to know that this is coming later down the road and for them the idea of being 
able to spare that for their child is a really big gift” (C) 
“I think that if it’s concerning for the couple and they want to choose to avoid a 
pregnancy that is at risk for early-onset Alzheimer then they can…” (E). 
Concern for the family 
  Eight percent (2/24) of participants were concerned that PGD for this reason, 
undervalued the life of the patient and other affected family members:  
“Just because they’ll have Alzheimer let’s say at 55, doesn’t mean that they might 
not win a Nobel Prize at 40…” (N) 
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“I would be concerned that the parent is undervaluing their life or the life of 
their family that had been affected with the disorder” (A). 
Eight percent (2/24) of participants stated children would not exhibit symptoms for many 
years and if a laboratory error occurred and an affected embryo were transferred, the 
child’s autonomy would be violated.  In total, 13% (3/24) of participants were concerned 
about the potential child’s autonomy: 
“The pre-child, the un-conceived child… can’t consent to that testing…we don’t 
have a fetus yet and the whole point is to avoid having a fetus who would have 
the gene…it is kind of semantic on one level but I see it on both as if there is not 
yet a person who would not need to consent…” (U). 
 Participants were next asked how they felt about PGD to identify embryos at risk 
for early-onset Alzheimer’s disease.  The two themes that emerged were: comfortable and 
patient autonomy. 
   2.4.3.3 Comfortable.  The majority of participants (83%, 20/24), were comfortable with 
PGD for this use; however, 60% (12/20) still had concerns, including: necessity of 
appropriate/thorough counseling, penetrance, patient’s perceptions, and propriety of this 
use of PGD.  Thirty-five percent (7/20) of the comfortable participants agreed this was an 
appropriate use of the technology: “If it is something that is important to the patient then 
I think that’s a valid use of the technology” (C).   
   2.4.3.4 Patient autonomy.  Eight percent (2/24) of participants were not comfortable 
using PGD in this situation but would support the family regardless.  Fifty percent (1/2) 
of those participants were concerned that a PSEN1 mutation was not 100% penetrant and 
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this was not an ideal use of the technology (2/24), however, they would support the 
patient as long as appropriate counseling occurred (3/24): 
“I feel kind of unhappy about that…I think a lot of what it comes down to is the 
level of education provided to the couple I think. And I feel pretty strongly in 
general that if they really have a good handle on what the limitations of the 
testing are and they understand …that it would be a predisposition, it would not 
be a given, and they still maintain that they are still really interested in pursuing 
it then I would be more comfortable” (S) 
“The biggest concern with that [BRCA mutations] could be discarding an 
embryo that while it carries the mutation a person may never have actually had 
cancer” (Q). 
Fifty percent (12/24) agreed they would support the patient’s decision and 33% (4/12) 
stated the patient should determine if the condition is “serious enough”: 
“For someone that watched a family member die from early-onset Alzheimer I 
can see why they would want to prevent having a child with it…so that they can 
give their child a better life. You know I feel like that is a completely unselfish 
reason to do PGD because it is not helping them at all because they probably will 
not live to see their child diagnosed with it. They are ensuring that their child 
will not get early onset Alzheimer” (B) 
“That particular family knows the disease better than anybody else. And if they 
feel that the disease is, you know, it is bad enough to warrant PGD and embryo 
testing then you know that is their decision” (D) 
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“I do not have a problem…because I care more about what the patient thinks 
than what I think. And I think that the patient’s concerns given her life 
experience, given her family experience that she is deciding for her own children, 
I am on board” (H). 
Eight percent (2/24) of participants believed that even though this is an option for 
patients, it was not necessarily the most ideal use of PGD: “I feel that while it might not 
be the ideal use of PGD it’s certainly not the worst use of PGD” (M).  
 Participants were asked about previous experiences counseling PGD cases for 
adult-onset conditions.  Twenty-five percent (6/24) have never counseled patients about 
PGD for adult-onset disorders, versus 75% (18/24) had previous experience with such 
cases.  Of the participants with experience (75%, 18/24), 56% (10/18) have had cases of 
Huntington’s disease and 5 of those 10 participants (50%), have also counseled for cancer 
predisposition syndromes (i.e. Lynch syndrome, FAP, and BRCA1/2).  In total, 67% 
(12/18) have counseled for cancer predisposition syndromes, 50% (6/12) of those that 
have counseled for cancer syndromes have not counseled other adult onset disorders.  
One participant (6%, 1/18) counseled a single patient about PGD for Alzheimer’s disease.  
 Regarding participants’ experiences counseling about PGD for adult-onset 
disorders, participants were asked about their concerns.  Of the 18 participants with 
experience, 33% (6/18) had no concerns and 67% (12/18) had concerns.  From this data 




   2.4.3.5 Non-disclosure/ Exclusion testing.  Fifty percent (5/10) of the individuals who 
have counseled about PGD for Huntington’s disease were concerned about non-
disclosure testing and 60% (3/5) of those participants were concerned patients might 
accidentally learn their mutation status: 
“My biggest concern was for the non-disclosure Huntington patients. Patients 
who themselves did not want to know their status but still wanted to do PGD to 
make sure their kids didn’t have it. And I felt there was a lot of psychosocial 
things that could be explored with those patients” (A) 
“My primary concern is that we were going to blow it somehow and we were 
going to give her, you know her results” (F) 
“There is still a test result out there and even though the lab and whoever is 
involved would do anything it can to make sure that information is not released, 
certainly there are instances where mistakes can happen” (T). 
Twenty-five percent (3/12) of participants were uncomfortable with discarding healthy 
embryos after exclusion testing for Huntington’s disease or carriers of cancer 
predisposition gene mutations: “You might be discarding embryos that are completely 
unaffected” (T). 
   2.4.3.6 Necessity of appropriate/thorough counseling.  Adult-onset conditions are 
complex and psychosocially challenging for couples and counselors.  Sixty-seven percent 
(8/12) of participants felt appropriate counseling was crucial when dealing with such 
cases: 
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“As long as the family or the couple is appropriately counseled about, the 
benefits and limitations of the technology and really understands the ins and outs 
and understands they are not using embryos that other than developing 
Alzheimer at an earlier than expected age but can have an otherwise, healthy life 
as long as they understand all of those aspects then I think they have the decision 
to make the reproductive choice that makes the most sense to them” (Q).  
Seventeen percent (2/12) of participants said PGD prevents suffering for future 
generations; although one of the two participants stated patients need to understand that 
risk to a potential child is not completely eliminated, as well as the potential for 
treatments to become available in the future: 
“So I think in those cases [cancer predisposition syndromes] we felt like it was 
definitely a good reason to prevent suffering in a person down the road” (S) 
“She was not interested in having her children necessarily be…having to go 
through that knowing that they already would probably have to deal with her 
health issues” (V) 
“We talked about the concerns that it’s not going to eliminate the risk of cancer 
and there could be…they could have a PTEN mutation and we didn’t test for 
that” (V).  
“I think that one [BRCA] is a little bit trickier for people because unlike 
Huntington’s there are actually things you can do to help prevent or reduce the 
risk of cancer…because that is something that there is at least some action that 
you can take I think that one is a little bit harder for people to understand” (T).   
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 Lastly, participants were asked how comfortable they were offering PGD for any 
adult-onset condition.  On a scale of one to five, where one was not comfortable at all and 
five was very comfortable, the majority of participants, rated themselves as a four (38%, 
9/24) or five (33% (8/24) (see Figure 2.1).  
   2.4.4 Use of embryos with genetic disease after PGD revealed no disease-free 
embryos to be available.  Participants were asked if they had any concerns regarding the 
transfer of a male embryo that carries a BRCA1 mutation when no unaffected embryos 
were produced.  Themes that emerged from discussion were: necessity of appropriate/
thorough counseling, patient autonomy, and implications of gender selection.  
   2.4.4.1 Patient autonomy.  Forty-two percent (10/24) understood couples’ reasoning for 
transferring a male carrier because the risk of cancer is less in a male.  Forty-two percent 
(10/24) agreed that it is the patient’s choice and 60% (6/10) of those 10 felt that couples 
were making a well informed decision.  One individual (4%, 1/24) was worried about the 
autonomy of the child since his genetic status would be known from birth: 
“They have completely eliminated that person’s decisions of whether or not to do 
testing as an adult. So I would be curious, I would want to explore with the 
parents about are they planning on telling their son this information and I do not 
know what the right answer to that questions is….you are also leaving that son 
with having to make the same decisions when he becomes of child bearing 
age” (V).  
!
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   2.4.4.2 Necessity of appropriate/thorough counseling.  Twenty-five percent (6/24) of 
participants had no major concerns and 50% (3/6) of those stated couples were choosing 
the “less risky” sex.  Twenty-nine percent (7/24) of participants were concerned the 
potential male child’s future children are now at risk of inheriting the mutation and 86% 
(6/7) of those seven participants agreed couples need appropriate counseling to be fully 
informed of the long term ramifications of transferring a male with a BRCA1 mutation.  
In total, 58% (14/24) stated that appropriate genetic counseling was important: 
“What if that poor man has daughters someday…a lot of things that they need to 
think about and those cases I would really really hope there is a genetic 
counselor helping them make the decision to implant that embryo. While a 
reproductive endocrinologist is very interested in getting them pregnant with a 
healthy baby, perhaps they are not equipped to really help the couple see long 
term ramifications of that decision” (A). 
Thirty-eight percent (9/24) responded couples may not understand a male’s cancer risk is 
not zero and could still develop cancer in his lifetime: 
“I think the most important thing in this situation is to make sure that they realize 
that a male embryo is not without risk…that there is increased risk for certain 
types of cancer…and to make sure they realize that it is not a totally risk free 
option” (R) 
“Just because it is a male, it does not mean that he would have no risk of any 
type of cancer” (S). 
!
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   2.4.4.3 Gender selection.  In total, 13% (3/24) felt this was more about gender selection 
than choosing a male embryo with “less risk” of cancer and one participant (33%, 1/3) 
responded that for females with a BRCA1 gene mutation, there is increased surveillance 
and medical management options available:  
“Breast cancer is somewhat preventable with increased surveillance and 
choosing a male while it reduces his personal risk of breast cancer, you know it is 
still not changing the risk for his children, his future offspring. Breast cancer is 
kind of a tough one because it is very manageable. And it feels like gender 
selection” (B).  
 Participants were asked how they felt, in general, about patients using affected 
embryos when no unaffected embryos were produced.  Common topics that emerged 
were comfort, propriety of the use of this technology, and patient autonomy.  Twenty-nine 
percent (7/24) were comfortable with patients transferring affected embryos when no 
unaffected embryos are produced and 100% of the seven participants agreed that it was 
the patient’s choice, which they would support.  In total, 75% (18/24) of participants 
would support the patient’s decision to transfer an affected embryo.  Thirty-three percent 
(8/24) did not think this was an appropriate use of PGD technology, however, 38% (3/8) 
would support the patient regardless.  
 Participants were asked if they had previous experience transferring affected 
embryos when no disease free embryos are available after PGD.  Twenty-five percent 
(6/24) had encountered cases where couples transferred affected embryos after PGD, 
75% (18/24) had not.  When asked which conditions couples have transferred affected 
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embryos for, two of these six participants stated the conditions were cancer predisposition 
syndromes and one of these participants reported a case of Charcot-Marie Tooth disease.  
Two participants reported cystic fibrosis cases and one reported a case for aneuploidy.   
 These six participants were asked if they had any concerns regarding cases where 
couples transferred affected embryos after PGD.  One participant (17%, 1/6) stated that 
she had no concerns and the other 83% (5/6) had concerns.  The main concerns that 
emerged were confusion and frustration.   
   2.4.4.4 Confusion and frustration.  Participants with concerns about patients 
transferring affected embryos used key words/phrases such as “why”, “I don’t 
understand”, “it’s confusing.”  For 80% (4/5) that had concerns, a main concern was the 
health of the child.  Sixty percent (3/5) felt this was not the intended use of the 
technology and two of those three participants were frustrated and confused by patients 
wanting to transfer affected embryos.  In total, 60% (3/5) expressed frustration/confusion:  
“I wanted to say to the family, “then why did you do the test,”…It is confusing…I 
think there is some frustration and then I think in my mind I am also saying to 
myself this could be a sick child. You have done all of this, and you are going to 
have a sick child, but then that is their decision” (A).  
One participant worked with a couple that transferred a non-viable aneuploid embryo 
after the physician stated the test may be inaccurate.  This participant expressed her 
frustration and anger in the following statement:  
“The whole point of people doing this they want to improve their pregnancy rate, 
they want to improve the implantation rate and they want to reduce the chance of 
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loss so you are talking about aneuploidy cases so they do not want to have a 
baby with a chromosome problem, they are not having a loss or a child born with 
something like Down syndrome. So to me it seems a little almost disingenuous for 
the physician to say well it may not be accurate let us just transfer” (I).  
This same participant stated it would only take one wrongful life lawsuit before 
reproductive endocrinologists would change their clinic policies:  
“I am sure all it will take is just one lawsuit where someone will get pregnant and 
it will be a funky mosaic…and the patient is going to say, you know what I, I 
don’t understand, now I am sitting here, I am in this horrible situation, my baby, 
my pregnancy is this and that and the other is probably going to say something 
like that and a lawsuit before physicians, IVF physicians will think a little bit 
more about whether they transfer these abnormals” (I).  
 In total, 100% (5/5) of the participants with concerns agreed that ultimately it was 
the patient’s choice to transfer affected embryos and regardless of their own personal 
beliefs, counselors would support patient autonomy. 
 Lastly, participants were asked how comfortable they were offering PGD to a 
patient that would use affected embryos for any condition.  On a scale of one to five, 
where one was not comfortable at all and five was very comfortable, the majority of 
participants, 71% (17/24), rated themselves as a three or less (see Figure 2.1).  
   2.4.5 PGD for a VUS for Marfan syndrome.  Participants were presented with the 
unique case scenario of using PGD for a VUS for Marfan syndrome and asked if this 
scenario raised any concerns for them and, if so, what concerns.  Thirteen percent (3/24) 
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of participants reported no concerns and 88% (21/24) raised multiple concerns.  A 
significant amount of participants shared many common concerns, from which, emerged 
several themes: uncertainty, directiveness of counseling provided, and lack of risk 
reduction.  For the “uncertainty” theme, two sub themes emerged: necessity of sufficient 
evidence and is PGD necessary.  
   2.4.5.1 Uncertainty. 
Necessity of sufficient evidence 
 Ninety-one percent (19/21) of participants were concerned that we cannot be 
100% certain a VUS is disease causing and 68% (13/19) of these individuals strongly 
encouraged family studies and felt more information/sufficient evidence was needed 
regarding the pathogenicity of the variant in question in order to feel more comfortable 
using PGD for a VUS.   In total, 71% (15/ 21) stated sufficient evidence from family 
studies was needed:  
“We actually request family studies…we actually thoroughly discuss with the 
couple doing PGD for this if it is not the cause you are not reducing risk” (I) 
“Because of the ambiguity…I would have a very lengthy discussion about…the 
fact that it is a VUS, it is not a known deleterious mutation, we could be deciding 
not to transfer embryos based on…incomplete information…I would also 
strongly suggest family studies…there would be a lot of counseling that would go 
with it” (K).  
A main concern for 10% (2/21) of participants was the exclusion of healthy embryos in 
the event that the VUS was, in fact, a benign polymorphism: 
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“I think the concern that you would be discarding embryos that are not actually 
affected…that is probably the biggest one” (R).  
Is this necessary? 
Forty-three percent (9/21) questioned if PGD was necessary and 78% (7/9) said it was not 
a proper use of the technology:  
“I feel uncomfortable with the use of PGD for a VUS…We do not even know 
whether it is the cause, does not seem like a great idea to me…” (S) 
“Just a straight up variant of unknown significance, then I do not really think 
that PGD has a big, large role to play in that” (P).  
   2.4.5.2 More directive counseling style.  Eighty-one percent (17/21) responded that 
PGD requests for a VUS would require more extensive counseling sessions and were 
more likely to use directive counseling in this situation: 
“I would have lots and lots and lots of talk about how unsure this is and this 
probably the scenario that I would be most likely to be directive that it is not a 
good idea to use PGD” (H). 
   2.4.5.3 Not reducing risk.  Fifty-two percent (11/21) believed that PGD for a VUS for 
Marfan did not reduce risk and a future child still could inherit Marfan syndrome and 
should still be assessed for a connective tissue disorder: 
“I would want to make sure that they fully understand that implanting embryos 
without the VUS still has some significant risk to create a child with Marfan 
syndrome” (L) 
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“I think in the case of with something like Marfan syndrome we would potentially 
recommend that they have a child evaluated for Marfan and know that it is 
something running in the family…kind of have them watched a bit more 
closely” (S).  
However, 4% (8/21) of participants that had concerns stated that it was not their place to 
inform a patient that they could not use PGD for a VUS: 
“I am never going to be in a position where I am absolutely going to tell a 
patient no I am not going to offer PGD because that is not my job…my job is to 
make sure they are informed” (L).  
 Participants were next asked how they felt about using PGD for a VUS for 
Marfan in particular.  Thirteen percent (3/24) were comfortable, and 38% (9/24) were 
uncomfortable: 
“Genetics is such a moving target in some ways especially when it comes to 
sequencing that it just makes me really uncomfortable to use something that you 
do not know for sure is definitively causative or linked with the disease” (N).  
From the other 11 participants, two common themes were established: proper use of the 
technology and evidence-based medicine.   
   2.4.5.4 Proper use of the technology.  Twenty-seven percent (3/11) questioned if this 
was a proper use of the technology and whether or not it is a waste of resources, 
including time, and money: 
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“ I hate to bring anything back to money because you cannot put a price on your 
child’s health and wellbeing but I feel like it would just be kind of a waste of 
resources unless we have reason to believe that the VUS is disease causing” (B) 
“It is kind of giving false hope to the parents” (J)  
“I think it is just not enough, that is not an appropriate use of the technology, 
because we are not sure that we are preventing the disease and thinking that we 
are when maybe we are not can have dangerous consequences” (C).  
   2.4.5.5 Evidence-based medicine.  The other 73% (8/11) felt that their comfort level 
would depend on the information/ data (i.e. family studies, research, laboratory 
classification etc.) available and counseling: 
“It just depends on how much investigative work has gone on prior to 
considering PGD” (D)  
“It would be concerning to me that we would be doing something without really 
having the science behind us, we would not really know if we are selecting for or 
against anything” (W). 
 When asked if participants had previous experience managing cases involving 
PGD for a VUS, 46% (11/24) had and 54% (13/24) had not.  The 11 participants with 
previous experience indicated a variety of disorders for which they have counseled for a 
VUS.  These conditions included muscular dystrophy (1/11), polycystic kidney disease 
(1/11), Fanconi anemia (1/11), cystic fibrosis (2/11), epidermolysis bullosa (1/11), 
hypertrophic cardiomyopathy (1/11), Treacher Collins syndrome (1/11), Cohen syndrome 
(1/11), and 2/11 indicated counseling for multiple conditions involving a VUS.  
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 Participants who have counseled PGD cases for a VUS were asked what concerns 
they had regarding their experiences.  All 11 participants had concerns and, again, 
common themes emerged.  These themes were: necessity of appropriate/thorough 
counseling and risks.  A sub-theme of appropriate counseling was “will this truly help the 
patient?”.  
   2.4.5.6 Necessity of appropriate/thorough counseling.  All participants stressed that 
patients need to be appropriately counseled for fully informed decision making and that 
counseling must included a special consent process regarding the uncertainties of PGD 
for a VUS: 
“It would require some really, really careful consenting” (V). 
Forty-six percent (5/11) stated that sufficient evidence indicating the VUS was disease 
causing was needed and that family studies should be performed to help determine 
pathogenicity.  
Will this truly help the patient? 
Fifty-five percent (6/11) felt there were numerous uncertainties and 50% (3/6) of these 
individuals questioned if the technology would truly be beneficial to the patient: 
“The main thing is counseling them appropriately that this may not be the cause 
and that doing testing for this may, one it may not be needed and two not reduce 
the risk whatsoever” (I).  
   2.4.5.7 Risks.  Eighteen percent (2/11) of participants were concerned healthy embryos 
would be discarded: 
“This could rule out embryos that are in fact healthy” (T).  
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 Lastly, participants were asked how comfortable they were offering PGD for a 
VUS for any condition.  On a scale of one to five, where one was not comfortable at all 
and five was very comfortable, the majority of participants 63% (15/24), rated themselves 
as a two or less and four percent (1/24) were very comfortable (see Figure 2.1). 
Figure 2.1 
On a scale of one to five (one being not comfortable at all, five being very comfortable) 
participants’ comfort levels regarding PGD for any adult-onset condition, transferring 
affected embryos when no disease free embryos are available, and PGD for a VUS. !
   2.4.6 General Questions.  General questions asked during interviews included ranking 
the three case scenarios from least controversial to most controversial, what PGD should 
and should not be used for, key factors in determining the appropriate use of PGD, what 
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uses.  Lastly, participants were asked if there were any other controversial uses of PGD 
they would like to discuss.   
 Participants were first asked to rank the three case scenarios, PGD for an adult-
onset disorder, transferring affected embryos when no disease free embryos are produced, 
and PGD for a VUS, from least controversial to most controversial.  Results were 
established from 23 participants as one participant felt she could not rank the scenarios in 
any order.  Overall, the majority (65%,15/23) of participants felt that PGD for an adult-
onset disorder was the least controversial, and PGD for a VUS was the most controversial 
(see Figure 2.2).  
 Of the six participants who counsel greater than 20 PGD cases per month, and 
work in a PGD laboratory or Reproductive Endocrinology clinic, 50% (3/6) stated that 
transferring affected embryos was most controversial and these same participants felt that 
PGD for a VUS was moderately controversial.  In total, 8/23 participants stated that PGD 
for a VUS was moderately controversial (6/8) or least controversial (2/8).   
 When asked what PGD should be used for, several themes emerged from the 
discussions.  Themes included: having a healthy child, what the patient perceives as 
severe/burdensome, conditions that are life limiting or cause a diminished quality of life, 
gender selection for X-linked conditions, and establishing clear risk of a genetic disorder. 
   2.4.6.1 Having a healthy child.  Twenty-five percent (6/24) of participants said that 
PGD should be used for “anything and everything” (L) to have a healthy child:  
“I think that PGD should be used for all of these things for helping people have 
the highest likelihood to have a healthy child” (E).  
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Figure 2.2.  
Participants’ ranking of the three case scenarios from least controversial to most 
controversial.  !
Chromosome abnormalities were identified as another legitimate use of PGD by 25% 
(6/24): 
“Most embryos have chromosome issues so the most important thing at this point 
is viability, PGD really helps us pick the embryos that are most likely to result in 
viability” (F).  
   2.4.6.2 What the patient perceives as severe/burdensome.  Forty-two percent (10/24) 
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“PGD should be used for…a serious, life threatening conditions…I think that the 
definition of severe that is a very broad term and I think it needs to be interpreted 
in the context of that particular family” (D). 
   2.4.6.3 Conditions that are life limiting or cause a diminished quality of life.  Fifty 
percent (12/24) responded that PGD should be used to avoid diseases that are life limiting 
or resulted in a diminished quality of life: 
“I think PGD should be used to prevent suffering of a future child” (B) 
“It really should be for medical purposes to avoid suffering, to avoid disease…
doesn’t necessarily have to be childhood onset, doesn’t necessarily have to be 
fatal but that is sort of where the avoiding suffering comes in” (N).  
   2.4.6.4 Clear risk of a genetic disorder.  Forty-two percent (10/24) said PGD should be 
used in cases where clear risk for a genetic disorder is established.  Eight percent (2/24) 
felt it should be used for highly penetrant conditions: 
“It should be used to test embryos for a clear risk for a significant medical 
issue” (K) 
“It should be used in cases where there is a clear risk for a known genetic 
condition being passed on in a family” (T). 
Gender for X-linked conditions 
Gender selection solely for X-linked conditions was accepted by 21% (5/24) of 
participants.  
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 Participants stated that PGD should not be used for gender selection (i.e family 
balancing, or just general gender preference), conditions that are not life limiting, and 
selecting for a genetic condition.   
   2.4.6.5 Gender selection.  The majority (71%, 17/24) agreed PGD should not be used 
for sex selection: 
“Barebones gender is not a disease and I tend to want to do this to help avoid 
disease” (I) 
“I would say sex selection, but even there I have to grapple with that it is that in 
my heart of hearts I believe that every baby born should be loved and so I believe 
that if a couple perceives that they would love a baby more because it is a girl or 
the baby is a boy, I should not stand in the way of creating that family” (G).  
   2.4.6.6 Conditions that are not life limiting.  Fifty-four percent (13/24) thought PGD 
for conditions that are not life limiting, including but not limited to positive trait 
selection, was not an appropriate use of the technology: 
“PGD should not be used to select for healthy traits, so I do not think it should 
be used for physical features…I enjoy human variation, I think that we all have a 
lot to offer” (A) 
“If somebody wants to prevent polydactyly, I think that would probably be a silly 
use of PGD… you know anything that is not really life limiting” (B) 
“It is a good tool to prevent a significant condition from being passed on but not 
necessarily something to be used to screen out a trait that a couple prefers not to 
have” (S) 
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“Male patterned baldness, if they wanted to use it for something insignificant 
then I would be like this is such a waste of resources, it is not like impacting 
quality of life” (X).  
Ambiguous genetic information 
 For 33% (8/24), PGD for ambiguous genetic information such as a VUS, single 
nucleotide polymorphisms (SNPs), and predisposition genes are other inappropriate uses 
of the technology: 
“SNPs that we do not know, you know like stuff on 23andMe you know the test 
that have very low relative risk odd scores or low odd risks. They probably do not 
have much of a place in this” (F) 
“I just get uncomfortable when I start thinking about the next generation 
sequencing and all the SNP chips and all that kind of stuff out there because you 
and I both know and my argument here is prenatally we don’t even know what the 
hell the SNPs mean so now you are going to do it on an embryo” (I). 
“Aside from VUSs…I think there are a lot of genes out there and predisposition 
type things that just are not ready for prime time in general…for example APOE 
and the Alzheimer increased risk, I think there are things out there so 
ambiguous…” (L).  
   2.4.6.7 Selection for a condition.  Eight percent (2/24) said selecting for a genetic 
condition, like deafness, was also inappropriate.  
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 For key factors in determining the appropriate use of PGD, four common themes 
emerged.  These themes were: diminished quality of life and life span, patient’s life 
experiences, established diagnosis, and patient education.   
   2.4.6.8 Diminished quality of life and life span.  Fifty-eight percent (14/24) responded 
that diseases that result in a diminished quality of life and therefore are medically 
significant were key in determining if PGD was appropriate: 
“I think it should be symptom severity. If you are talking about someone not 
being able to have a normal life or potentially having a chance of a shortened 
lifespan then that is a reasonable thing to talk about” (A) 
“Overall the impact on life or quality of life or what the disease burden is” (Q). 
   2.4.6.9 The life experiences of the patient.  For 38% (9/24), the patient’s life 
experiences influenced whether or not PGD should be used: 
“It is their experience that matters, it is not my opinion that matters…For some 
of them they really do feel a serious burden and a large desire to avoid passing it 
on to children and so it became very easy to just make sure that every patient 
knew about their options and to let them then direct me regarding how much they 
wanted to know about it” (C). 
   2.4.6.10 There is an established diagnosis in the family.  Thirty-three percent (8/24) 
agreed that PGD was appropriate for an established diagnosis and known mutation: 
“I think the biggest thing is to make sure that you are operating, that you are 
working with things you know, that you can confirm the mutation” (W). 
!
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   2.4.6.11 Patient education.  Lastly, 42% (10/24) determined that PGD was appropriate 
if the patient was well educated: 
“I think the most important thing is education, I think that our biggest job is to 
make sure that patients understand the process, the goal of the testing and you 
know possible hang ups and what the potential outcomes are and beyond that I 
think that you know your biggest job is to provide education on it and it is the 
patient’s job to figure out what options are going to be best for them” (H).   
 Participants were next asked what the future holds for the use of PGD and if they 
had any concerns regarding its potential uses.  Themes that were established included: 
testing for things that are not medically significant, expansion of genetic testing of 
embryos, accessibility, misconceptions about PGD, lack of genetic counselors in fertility 
clinics, and advancements in PGD technologies.  A sub-theme of testing for non-
medically significant traits was eugenics.   
   2.4.6.12 Expansion of genetic testing of embryos.  Fifty-eight percent (14/24) believe 
expansion of genetic screening of embryos, through next generation sequencing and 
whole exome sequencing, is inevitable and 57% (8/14) of these participants were 
concerned: 
“You know what is funny about that to me?…That we will not be able to put back 
any embryos” (G) 
“You are not going to have any “normal” embryos” (I) 
“If we start testing for “everything”, and association risk and what not, we are 
not going to have any embryos to transfer because we are all at risk for 
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something, we all carry things, we all, we are human beings, we are susceptible 
to disease, sometimes pretty severe disease, so I, we need to keep it in check to a 
certain degree (K).  
   2.4.6.13 Testing for traits that are not medically significant.  Thirty-eight percent 
(9/24) felt eventually more ambiguous, mundane, non-medically significant traits would 
be commonly tested for and all nine of these participants along with seven other 
participants, 67% (16/24), were worried about this occurring: 
“If we start to do PGD you know for what we might term less severe conditions 
or just multifactorial conditions we are going to reduce a lot of the variation in 
our society and I would hate to see a society of perfect people where the few 
people who are not perfect are left out” (B) 
“With the use of exome sequencing it is going to be a lot more common for 
people to do PGD for non-medical reasons…What could be the evolutionary long 
term…what are going to be the down stream affects of …other mutations that 
when we do that become more evident…are we going to find out that when we 
select for those genes that there are unintended consequences…is it going to 
lower the diversity in the population” (M). 
Eugenics 
 Forty-four percent (7/16) of this group of participants are concerned this would 
lead us down the path of eugenics and a “GATTACA” like future and 29% (2/7) were 
worried people may someday be required to do PGD: 
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“I do not want to live in GATTACA you know I do not want to live in a society 
where people have to use PGD to reproduce, I do not want to live in a society 
where we will not let people have kids on their own, I do not want us to have to 
test every embryo and make everybody do that to have a child that that sounds 
crazy but…that does scare me” (F). 
However, 8% (2/24) of participants were not concerned about the potential uses, such as 
positive trait selection, because genetics are extremely complicated: 
“I do not have any concerns…that is how much I believe in how stupid we are. 
And that is how much I believe in the complexity of life and that is how much I 
believe that yes so when things happen in a lab they are incredibly artificial. And 
once again, I might be naive, is that health care professionals have their own 
internal checks and balances that we will never run on luck. And we will never 
do things that are unethical and immoral” (G). 
   2.4.6.14 Accessibility.  With regards to accessibility, affordability, and improved 
techniques, 42% (10/24) of participants hoped or believed more people will have access 
in the future: 
“Unfortunately it remains unavailable due to cost for a lot of my patients, so that 
is a concern that I have, I wish it were more available for those patients and I do 
not know that if it is ever going to become too available because lots of patients 
are not going to be ever willing to go through the process of IVF which is what is 
required for PGD” (L). 
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However, 17% (4/24) are worried about possible class discrimination with only the 
wealthy being able to afford PGD: 
“People just you know they feel that everything they want and they want it now 
immediately or ten minutes ago, because it is expensive, it is very expensive and 
a lot for people to go through, it is definitely its own niche [of people]” (R).  
   2.4.6.15 Misconceptions about PGD.  Seventeen percent (4/24) were concerned about 
the public’s/patient’s misconceptions: 
“ I often get questions from families “well what can we test for?” Sometimes 
jokingly but sometimes partially serious they ask “do we have the ability to test 
for intelligence?” and things like that…I think the general public has 
misconceptions about what we actually can and cannot do” (Q) 
“In Hollywood right now it [genetics] is evil, it is the bad guy. Every zombie 
movie is because of a genetically engineered virus and I always like to see how 
science fiction kind of predicts society’s biggest fears and most of them happen to 
be genetics right now and it is fun to talk to people and say you know what 
honestly, that [designer babies] is not to far in the future, but no in medical 
genetics that not really the focus” (U).  
   2.4.6.16 Lack of genetic counselors in the reproductive endocrinology field.  Because 
there are not enough genetic counselors in fertility clinics, 25% (6/24) were concerned 
that reproductive endocrinologists will inappropriately use PGD: 
 “I am more concerned about the REIs, but I think most PGD labs…understand 
why PGD was developed and would not be comfortable offering that to families 
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and I would hope that REIs would not feel comfortable offering it to their 
patients” (D) 
“There is going to be an extremely large need for genetic counselors and very 
thorough consenting and very thorough data analysis, I do not think we have the 
man power for that so my fear is that things are going to fall in the hands of the 
reproductive endocrinologist and things are going to be done irresponsibly” (V). 
   2.4.6.17 PGD is advancing.  Finally, 8% (2/24) were adamant most people do not 
realize how fast this field is advancing: 
“People do not really know what is happening in the field, it is moving very 
quickly, we tend to focus on things that are hypothetical, they are actually 
happening…We like to think about “hey you know should we pick BRCA that 
sounds fine”…it is not a scenario anymore, it is actually happening, we need to 
be ready for it and I don’t think we are” (F).  
 Lastly, participants were asked if there were additional controversial aspects of 
PGD.  Forty-six percent (11/24) of the participants felt the study scenarios captured the 
essence of controversial indication for PGD and the slippery slope that genetic counselors 
find themselves traveling.  The other 54% (13/24) of participants mentioned subjects 
such as non-disclosure testing (8%, 1/13), BRCA positive patients being put on injectable 
hormones (8%, 1/13), preimplantation genetic screening (8%, 1/13), HLA matching (8%, 
1/13), the lack of guidelines (15%, 2/13),  and gender selection (8%, 1/13) as other 




 This study is one of the first to assess the opinions of genetic counselors regarding 
controversial applications of PGD.  Although practice guidelines put forth by the 
American Society of Reproductive Medicine (ASRM) address specific topics of PGD, 
such as adult-onset conditions, there are still gaps in the information regarding 
applications that are controversial.  This study looked at three such applications 
including: PGD for adult onset predisposition to disease, use of embryos with genetic 
disease after PGD revealed no disease-free embryos to be available, and PGD for a VUS.  
Genetic counselors who have counseled PGD cases were questioned about these three 
applications, and from these discussions themes were established from their opinions, 
thoughts and concerns.   
 From the discussions we determined that certain factors influence counselors’ 
comfort of PGD being used for adult-onset conditions, transferring affected embryos 
when no disease free embryos are available, and testing for a VUS.  Themes common to 
all three scenarios included: the need for appropriate/thorough counseling, the importance 
of the genetic indication, patient perceptions, and respect for patient autonomy in 
decision making.   
   2.5.1 Need for appropriate/thorough counseling .  Appropriate counseling included 
review of the benefits and limitations of PGD, education about the disease, and 
addressing psychosocial elements.  In order for patients to be fully informed, several 
topics should be covered.  For adult-onset disorders, many genes, including PSEN1 and 
BRCA mutations, are considered predisposition genes that are not 100% penetrant.  
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Mutations in predisposition genes cause increased susceptibility to developing a 
particular disease but do not guarantee that symptoms will occur in the person’s lifetime 
(Ormondroyd et al., 2012).  For some counselors, PGD for predisposition genes or genes 
that exhibit reduced penetrance is more difficult to accept as there is not a 100% risk to 
the individual.  Part of this concern is that we could potentially be discarding embryos 
that are otherwise healthy and these potential children could have led fulfilling lives.  
Therefore, for some counselors, the penetrance of the condition can affect how 
comfortable they are using PGD.  Another key discussion to have with patients is about 
the potential of disease treatments or potential cures in the future.   
 While the risk of cancer developing in a BRCA positive male is significantly less 
than a female’s risk, it is not negligible.  Also, a BRCA positive male’s future children are 
at 50% chance of inheriting the same mutation.  The potential male child resulting from 
the transfer of a known BRCA positive embryo may someday be put in the position of 
deciding to use PGD for his own children.  Although this type of scenario has the 
potential for causing “uneasy” feelings in genetic counselors, most participants in this 
study understood the patient’s reasoning for selecting a male embryo.  Per Savulescu 
(2001), if a couple knowingly chooses to transfer an embryo that is affected with a 
genetic disease, then the medical professional should not express agreement or 
disagreement about this decision. 
 Counseling for PGD should include discussion of all possible outcomes, so that 
on the day of embryo transfer, couples are not forced to make immediate, emotionally 
laden decisions.  This includes the possibility that all embryos may be affected.  
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Therefore, genetic counselors need to assist patients in considering a course of action for 
each potential outcome.  Patients also need to understand a potential child’s risk of 
developing the disorder in question and the long term ramifications of such a decision.  
 Given the increased use of genetic testing through next generation sequencing 
panels, microarray, and whole exome/genome studies, requests to use PGD to test for a 
VUS is likely to increase.  As a VUS has not been defined as clinically significant or 
predictive of an individual’s phenotype, the appropriateness of PGD for a VUS is 
debatable.  The presented scenario of PGD for a VUS for Marfan syndrome raised 
multiple concerns for the majority of participants in this study, and participants expressed 
concern about PGD for a VUS for any genetic condition.  Because a VUS is not 
definitively disease causing, transferring embryos that lack the VUS does not guarantee 
that the potential child will not have the disease (Reiff et al., 2012).  In addition, 
discarded embryos that carry the VUS could be disease free.  Most participants expressed 
that sufficient evidence is needed to support that the VUS was disease causing including 
research, laboratory classification, and family studies to determine if the VUS tracks with 
affected family members.   
  According to the principle of non-directive counseling, medical personnel should 
provide patients with information about risks and options to reduce these risks 
(Savulescu, 2001).  Although non-directive counseling is a central tenet of the genetic 
counseling profession, a more directive counseling style may need to be considered in 
both the situations of PGD for a VUS and when considering transferring affected 
embryos when no disease free embryos are available.  Patients need to be extensively 
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counseled that selecting against a VUS may not be reducing the risk of passing on the 
condition in question, and children born after PGD should still be evaluated by a 
geneticist for the disease.  On a more practical note, unless there is evidence in support of 
the pathogenicity of the variant, some believe PGD for a VUS is not an appropriate use of 
the technology and may be a misuse of patient’s time and money, as well as medical 
resources.  However, some people believe that PGD should be used to reduce uncertainty, 
and therefore PGD for a VUS would be appropriate since that would accomplish this 
goal. 
   2.5.2 Patient Perceptions.  Counselors felt it was important to discuss how 
burdensome a disease has been in the patient’s life.  Many factors are considered in 
determining which conditions are labeled as “serious” including penetrance, potential for 
treatment, progression, age of onset, and severity of symptoms (Krahn, 2009).  However, 
it is important to remember that every patient’s perception of what is “serious” or 
“burdensome” is different (Miller & Levine, 2013).  Genetic counselors should 
specifically address the unaffected spouse and discuss how he/she feels about caring for a 
new baby and the spouse, both with a genetic condition, some that are potentially life 
threatening. 
   2.5.3 Patient Autonomy.  For many counselors, regardless of their own personal 
feelings, patient autonomy was of utmost importance.  Ultimately, patient’s choices will 
affect their own lives, and it is not the position of a provider to say whether they can or 
cannot use PGD.  Genetic counselors have a responsibility however, to ensure patients 
are appropriately counseled and fully informed about the benefits and limitations of PGD.  
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Most genetic counselors believe patients have procreative autonomy.  The basis of 
procreative autonomy is that couples are free to decide what kind of children to have, as 
well as when and how to have these children (Savulescu, 2001).   
   2.5.4 General Questions  
   2.5.4.1 Least controversial and most controversial scenarios.  Overall, the majority of 
participants stated PGD for a VUS was the most controversial scenario of the three 
scenarios presented, while PGD for adult-onset conditions was the least controversial.  
This finding was most likely due to the uncertainty of a VUS being disease causing.  
Having an established diagnosis with a known disease causing mutation made 
participants more comfortable offering PGD. 
 Testing for an adult-onset condition, with an identifiable mutation, was easier for 
participants to accept, possibly because it is no longer considered a “novel” idea and has 
been done more frequently.  With expansion in genetic testing, more “novel” ideas, like 
PGD for a VUS, and PGD for ambiguous genetic information will create unease among 
professionals.  In the beginning, new concepts are prone to be controversial and cause 
discomfort.   
 A counselor’s experience with PGD may have influenced their opinions.  Six 
genetic counselors reported having counseled 20 or more PGD cases per month.  Four of 
these genetic counselors work in a PGD laboratory setting and the other two work in 
Reproductive Endocrinology clinics.  We determined that the majority of this subset of 
participants that felt transferring affected embryos was most controversial, worked in a 
PGD laboratory or Reproductive Endocrinology clinic.  A potential explanation could be 
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that genetic counselors in these two settings feel that the intended use of the technology is 
to transfer unaffected embryos.  Of the participants that stated PGD for a VUS was 
moderately or least controversial, half of them worked in these two settings.  This could 
be because they have more experience addressing VUS cases and the issues are less 
novel.   
   2.5.4.2 Counselors opinions regarding what PGD should and should not be used.  
Participants stated that PGD should be used for the purpose of having healthy children.  
The ultimate goal of PGD is to produce healthy children and avoid suffering.  In order for 
this to be possible, participants felt that there needs to be a clearly established risk of an 
inherited genetic disorder within a family.   
 Half of the participants also felt PGD was appropriate for conditions that are life 
limiting or cause reduced quality of life.  It is important to consider a patient’s perception 
of which conditions are serious or burdensome enough to warrant the use of PGD.  Most 
providers cannot fully understand or appreciate the experiences of individuals whose 
families are stricken with genetic conditions.  For some, having a child with a BRCA 
mutation may be acceptable because there is treatment, increased surveillance and 
medical management options.  For another whose family has been devastated by the 
disease, they may decide that the disease needs to “end with them” and not be transmitted 
to future generations. 
 When considering what PGD should not be used for, participants stated that 
gender selection, testing for ambiguous genetic information, HLA matching and selecting 
for (rather than against) a genetic condition were inappropriate.  With regard to gender 
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selection, the majority felt PGD should not be used as gender is not a “disease.”  
However, the caveat here is that for X-linked conditions, gender selection is the easiest 
method of selecting out embryos and therefore was considered the only appropriate 
reason for gender selection.   
 The majority of counselors raised concerns about testing for conditions that are 
not necessarily life limiting or testing for ambiguous genetic information.  For example, 
positive trait selection is not life limiting.  Over half of the participants felt that PGD 
should not be used to select for “healthy traits” such as hair color, eye color, height, or 
athleticism.  A common reason for this belief was that human variation was appealing to 
participants.  Participants expressed that PGD should be used to prevent significant health 
problems, but should not necessarily be used to select for traits that a couple prefers to 
have.  Another consideration is that testing for traits that do not impact quality of life is a 
waste of resources.   
 Participants indicated that ambiguous genetic information included: VUSs, single 
nucleotide polymorphisms (SNPs), and predisposition genes.  With the development of 
tests such as that provided by the company 23andMe, in which the genetic information 
present often has low relative risk scores, people may request PGD for SNPs and 
predisposition genes.  The problem is that with VUSs, SNPs and predisposition genes 
there is not enough evidence to support using these indications for PGD.   
   2.5.4.3 Key factors in determining the appropriate use of PGD.  There were five 
common themes that were key in determining appropriate uses of PGD.  The majority of 
participants felt that PGD was an appropriate use if conditions were life limiting and 
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resulted in a diminished quality of life.  Participants were more comfortable when 
symptom severity and disease burden were significant.  The patient’s life experiences 
were a common theme throughout the study and was key in determining the 
appropriateness of PGD.  Ultimately, a patient’s experiences superseded counselor 
opinions.  Also, participants were more at ease with offering PGD if there was an 
established diagnosis with a known pathogenic mutation.  Last, participants believed 
patient education was important in determining if PGD was appropriate.  Genetic 
counselors must ensure that the patient is well educated about the PGD process, the 
benefits and disadvantages, and the potential outcomes of PGD, and ultimately, patients 
must decide on the course of action that is most appropriate for their families.  
   2.5.4.4 The future of PGD and counselors concerns about its potential uses.  Overall, 
the majority of counselors interviewed had concerns about the potential uses of PGD.  
Participants responded that PGD is likely to eventually be used to test for non-medically 
significant traits, that there would be expanded testing of embryos, and that accessibility 
would change.  Participants had concerns about these eventual uses but were also 
concerned about patient/public misconceptions, and the lack of genetic counselors in 
fertility clinics.  However, two participants were not concerned about future uses, such as 
positive trait selection, because of the complexity of genetics, and how difficult it would 
be genetically manipulate or engineer individuals.   
 The majority of genetic counselors interviewed believed that next generation 
sequencing and whole genome/exome sequencing will be used to screen embryos and 
half of these participants were concerned about this testing.  The concern was that no 
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“normal” embryos will be available for transfer because every embryo is susceptible to 
disease.  If these extensive tests are used on embryos, the pool of embryos would most 
likely be eliminated.  Additionally, one must consider who will be responsible for 
deciding which embryo to transfer after WGS or NGS, will it be the parent or the 
physician? 
 Participants also felt that eventually PGD is likely to be used to test for more 
ambiguous, mundane, non-medically significant traits.  The majority were concerned 
about this potential use of PGD.  A concern was that there will be unintended 
consequences when selecting for certain traits, such as reducing genetic variation within 
the population.  Another concern is that this will lead us down the path of eugenics 
towards a “GATTACA” future.  GATTACA is the title of a science fiction movie where 
society is driven by eugenics and children are artificially created to have the most 
advantageous traits.  Some participants expressed worry that people may someday be 
required to do PGD, as depicted in this film.    
 Many participants hoped that PGD will become more accessible, affordable, and 
technically improved.  Unfortunately PGD is currently unavailable to many patients 
because of its high cost.  However, even if PGD does become affordable, many “patients 
are not going to be ever willing to go through the process of IVF” (F), because of all that 
it entails.  Some participants were concerned about possible class discrimination, where 
only the wealthy are able to afford PGD.   
 Another concern for participants was the public’s/patient’s misconceptions about 
PGD.  In many movies today, genetics is a central theme and this and other popular 
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media may create misconceptions.  People often assume that it is possible to test for 
every disease, pick and choose physical characteristics, or engineer “designer babies.”  
Efforts to disperse these misconceptions are needed in order for patients and the medical 
community to understand this is not the primary focus in medical genetics.   
 A main issue that emerged from participants is that there are not enough genetic 
counselors involved in the fertility field.  Most fertility clinics do not work in association 
with genetic counselors and several participants in this study expressed worry that 
reproductive endocrinologists will inappropriately or irresponsibly offer PGD.  Genetic 
counselors could be extremely valuable in these environments, offering guidance for 
screening and testing of both the couples and their embryos.   
   2.5.5 Study Limitations.  The group of participants was limited to genetic counselor 
members of the NSGC that have experience counseling PGD cases.  The majority of 
participants were young and inexperienced, which may have affected results.  More 
experienced PGD counselors may be more comfortable with controversial scenarios.  
Biases may have been created as each scenario is just one example and perhaps 
participants would have had different responses to different scenarios.  Additionally, there 
is likely a response bias since genetic counselors who do not counsel for PGD might be 
less likely to offer their participation.  It should also be considered that some participants 
are guided by laboratory policy, and may not have expressed their own opinions and 
instead expressed the laboratory’s opinions.  Also, only the opinions and attitudes of 
genetic counselors were reported in this study.  It does not examine the thoughts and 
!64
perceptions of the reproductive endocrinologists or other individuals involved in caring 
for patients who are contemplating PGD, where different perspectives may be present.   
   2.5.6 Practice Implications.  Our findings shed light on genetic counselors’ 
perceptions about current and future uses of PGD.  We have identified key areas where 
tension between advances in PGD and genetic counselors experience significant ethical 
dilemmas or controversy.  Awareness of these key areas will aid genetic counselors in the 
practice setting and also provide areas for needed research in the future.  It will also 
ensure that genetic counselors who are not currently involved with PGD are cognizant of 
recent advances in the potential role for genetic counselors in the fertility setting. 
2.6 Conclusion 
 With advancements in genetic diagnostic technology, PGD has expanded to 
incorporate indications that may be considered controversial.  For controversial 
applications of PGD, five common themes emerged with regards to determining if PGD 
was appropriate.  Participants stated PGD is appropriate for conditions that are life 
limiting and cause a diminished quality of life.  When symptom severity and disease 
burden were significant, participants were more comfortable.  Having an established 
diagnosis with a known pathogenic mutation, also contributed to counselors’ comfort.  
Patient’s life experiences were also key in determining if PGD was appropriate.  
Participants felt that thorough counseling and education of patients was crucial; however, 
patient autonomy superseded counselors’ concerns.  Even though PGD for certain 
conditions causes discomfort for some counselors, the value of the technology was 
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recognized by all participants and ultimately, patients need to decide on a course of action 
that is most appropriate for their families.   
 As more novel uses of PGD are performed, counselors will need to quickly adapt.  
Common indications for PGD, like PGD for adult-onset disorders, was initially 
controversial, however, as more individuals have sought PGD for this reason, genetic 
counselors have become more at ease with PGD for this use.  It is possible that eventually 
genetic counselors may reach the same level of comfort with using PGD for a VUS and 
other controversial applications.  It is our hope that this study will bring attention to this 
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other controversial applications.  It is our hope that this study will bring attention to this 
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Appendix A: Invitation letter to Participants !
Invitation to Participate: Genetic Counselors Opinions and Attitudes Towards Uses of 
PGD !
Dear Genetic Counselor, 
 You are invited to participate in a master of science thesis research study at the 
University of South Carolina School of Medicine. The objective of this study is to 
explore the opinions and attitudes of genetic counselors when dealing with controversial 
uses of preimplantation genetic diagnosis.   
 Participation in this study is intended to benefit the genetic counseling field by 
revealing how genetic counselors view various issues.  We believe that the study results 
will demonstrate the opinions and attitudes of counselors regarding use of PGD as no 
previous studies have focused on this topic.  We feel that this study will add information 
to the discussion concerning applications of PGD technology. 
 If you decide to participate, you will be asked to complete a qualitative survey 
over the telephone asking a series of questions about various issues that you may 
encounter in practice.  Your verbal consent will be obtained before the survey begins.  
The interview should take approximately 30 minutes. You do not have to answer any 
questions that you do not wish to answer and you can stop taking the survey at any time. 
The interview will be recorded to ensure accuracy; all identifying information will be 
deleted after the interview.  
 If you have any questions, or would like more information, please contact the 
principal investigator (or my faculty advisor, Janice Edwards), using the contact 
information below.  If you have any questions about your rights as a research participant, 
you may contact the Office of Research Compliance at the University of South Carolina 
at 803-777-7095. Thank you for considering participating in this research project.  Your 
input is invaluable, and we appreciate your time! 
!
Kristen Everton   
Genetic Counseling Intern   
University of South Carolina School of 
Medicine  
Genetic Counseling Program   
2 Medical Park, Suite 103   
Columbia, SC  29203  
phone: (954) 292-0690 
Kristen.Everton@uscmed.sc.edu  
Janice G. Edwards, MS, CGC 
Clinical Professor and Director, 
University of South Carolina School of 
Medicine 
Genetic Counseling Program 
2 Medical Park, Suite 103 





Appendix B: Verbal Consent !
You are invited to participate in a master of science thesis research study at the University 
of South Carolina because of your experience with preimplantation genetic diagnosis 
(PGD) cases.  The purpose of the survey is to explore the opinions and attitudes of 
genetic counselors when dealing with controversial uses of PGD.  This telephone 
interview will be recorded and all identifying information will be deleted after the 
interview.  Your participation is voluntary and you may skip any questions that you do 
not feel comfortable answering.  You may stop participating at any time.  This survey 
should take approximately thirty minutes.  If you have any questions about your rights as 
a research participant, you may contact the Office of Research Compliance at the 





Appendix C: Survey !
I.  Introduction/Directions 
 You are invited to participate in a thesis research study at the University of South 
Carolina School of Medicine.  The objective of this study is to explore the opinions and 
attitudes of genetic counselors when dealing with controversial uses of preimplantation 
genetic diagnosis.  You will be presented with three case scenarios regarding 
controversial uses of PGD.  For each scenario, you will be asked several open ended 
questions.  At the end, several general questions regarding the use of PGD will also be 
asked.  The survey should take approximately 30 minutes to complete.  
II. Demographic Questions 
A. Gender/ Age: 
B. Number of years in practice as a genetic counselor: 
C. Number of months/years you have counseled for PGD: 
D. Number of all PGD cases seen per month:  
E. Location of practice: State 
F. Setting of practice: PGD Laboratory Setting, Reproductive Endocrinology 
Setting, Other 
III. Case Scenarios 
A. PGD for an Adult-Onset Condition: A woman and her husband request PGD for 
early onset Alzheimer.  A disease causing mutation in the PSEN1 gene has been 
identified.  PSEN1 mutations account for 70% of early onset Alzheimer cases.  
These cases are diagnosed before the age of 65.   
1. Does this scenario for early onset Alzheimer raise any concerns for you and if 
so, what concerns are raised? 
2. How do you feel about using PGD to identify embryos at risk for early onset 
Alzheimer? 
3. Have you had any cases that included using PGD for an adult-onset condition?  
a) Describe the case  
b) What was the condition?  
c) Did you have any concerns? 
4. On a scale of 1 to 5 (1 being not comfortable at all, 5 being very comfortable), 
how comfortable are you offering 
a) PGD for any adult-onset condition? 
B. PGD to Select for a Genetic Condition: A couple requests PGD because of a 
family history of breast cancer.  The mother carries a disease causing mutation in 
the BRCA1 gene.  All of the female embryos and the only male embryo are found 
to carry the mutation as well.  The couple decides to implant the only male 
embryo.   
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1. Does this scenario raise any concerns for you and if so, what concerns are 
raised?How do you feel about your patients using affected embryos when no 
unaffected embryos are produced? 
2. Have you had any cases that you have managed personally that included 
transferring affected embryos after PGD?  
a) Describe the case 
b) What was the condition? 
c) Did you have any concerns?  
3. On  a scale of 1 to 5 (1 being not comfortable at all, 5 being very 
comfortable), how comfortable are you offering PGD to a patient that will  
a) Use affected embryos for any condition 
C. PGD for a Variant of Unknown Significance (VUS): A couple requests PGD 
because the husband has Marfan syndrome.  However, no known mutation was 
identified.  Instead, a VUS was found.  The couple wants to use PGD to select 
against the VUS, since there is the possibility that it may be the cause of the 
husband’s Marfan syndrome.  Individuals with Marfan can be mildly to severely 
affected, those that are mildly affected can go undiagnosed for their entire life and 
have no major health concerns.   
1. Does this scenario raise any concerns for you and if so, what concerns are 
raised? 
2. How do you feel about using PGD for a VUS for Marfan? 
3. Have you had any cases that you have managed personally that included using 
PGD for a VUS?  
a) Describe the case  
b) What was the condition?  
c) Did you have any concerns? 
4. On a scale of 1 to 5 (1 being not comfortable at all, 5 being very comfortable), 
how comfortable are you offering PGD for  
a) A VUS for any condition? 
D. General Questions:  
1. Rank the three case scenarios, according to how you personally feel, from 
least controversial to most controversial. 
2. What do you feel PGD should be used for? 
3. Is there anything you feel PGD should not be used for? 
4. What are some key factors in determining the appropriate use of PGD? 
5. What do you believe the future will hold for the use of PGD?   
6. What concerns you about its potential uses? 
7. Is there anything else you would like me to know about the controversial uses 
of PGD? 
IV. Thank you. 
 Thank you for your participation in this thesis research study, it has been greatly 
appreciated.  Your input is invaluable.  It is my hope that this research will provide 
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valuable perspectives from genetic counselors who work with PGD to the discussion 
concerning controversial applications of the technology.  !
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